Xilio Therapeutics, Inc. 8-K

What Happened

• Xilio Therapeutics, Inc. (XLO) filed a Form 8-K on March 12, 2026 reporting a Certificate of Amendment to effect a 1-for-14 reverse stock split of its common stock. The Reverse Stock Split becomes effective at 5:00 p.m. Eastern Time on March 13, 2026. The action was taken to help the company comply with Nasdaq Capital Market minimum bid price requirements, as previously disclosed in its proxy materials.

Key Details

• Reverse split ratio: 1-for-14 (every 14 shares of issued and outstanding common stock will be combined into 1 share).
• Effective timing and trading: Effective 5:00 p.m. ET on March 13, 2026; common stock expected to trade on a post-split basis at market open on March 16, 2026 under the existing symbol "XLO." New CUSIP: 28422T209.
• Fractional shares: No fractional shares will be issued; holders entitled to fractional shares will receive a cash payment in lieu of fractional shares.
• Capital structure effects: The split does not change the number of authorized shares or par value; outstanding equity awards and shares available under equity incentive plans will be adjusted proportionately per plan terms.

Why It Matters

• For investors, a reverse stock split reduces the number of outstanding shares and increases the per-share price proportionally, which can help the company meet Nasdaq listing standards. The company's overall market value (market cap) is generally unchanged by the split itself, though fractional-share cash-outs and rounding may slightly affect individual holdings. Adjustments to stock-based awards will affect the share counts and exercise prices of existing grants according to plan terms. The 8-K includes the Certificate of Amendment and an attached press release.